EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Oncoinvent ASA's Enterprise Value is kr69.24 Mil.
Oncoinvent ASA's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was kr-138.47 Mil. Therefore, Oncoinvent ASA's EV-to-FCF for today is -0.50.
The historical rank and industry rank for Oncoinvent ASA's EV-to-FCF or its related term are showing as below:
CHIX:ONCINo'
s EV-to-FCF Range Over the Past 10 Years
Min: -12.31 Med: -1.45 Max: 1.25
Current: -0.49
During the past 11 years, the highest EV-to-FCF of Oncoinvent ASA was 1.25. The lowest was -12.31. And the median was -1.45.
CHIX:ONCINo's EV-to-FCF is ranked worse than 100% of 330
companies
in the Biotechnology industry
Industry Median: 16.33
vs CHIX:ONCINo: -0.49
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Oncoinvent ASA's PE Ratio (TTM) for today is calculated as:
Oncoinvent ASA's share price for today is kr1039.90731.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Oncoinvent ASA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was kr-157.076.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Oncoinvent ASA EV-to-FCF Related Terms
Oncoinvent ASA EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Oncoinvent ASA's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:ONCINO vs VRTX, REGN, ALNY: EV-to-FCF Comparison
For the Biotechnology subindustry, Oncoinvent ASA's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncoinvent ASA EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncoinvent ASA's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Oncoinvent ASA's EV-to-FCF falls into.
Oncoinvent ASA's current Enterprise Value is kr69.24 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Oncoinvent ASA's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was kr-138.47 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncoinvent ASA (CHIX:ONCINO) has a EV-to-FCF of -0.50 as of Jul. 09, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Oncoinvent ASA and its competitors. According to the industry distribution chart, Oncoinvent ASA ranks #999999 out of 330 companies in the Biotechnology industry.
Is Oncoinvent ASA's EV-to-FCF too high?
Oncoinvent ASA's current EV-to-FCF is -0.50. Based on the distribution chart, Oncoinvent ASA ranks #999999 out of 330 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Oncoinvent ASA has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Oncoinvent ASA's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oncoinvent ASA ranks #999999 out of 330 companies for EV-to-FCF. This places Oncoinvent ASA in the lower half of its industry. The industry median EV-to-FCF is 16.33. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.33, based on 330 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Oncoinvent ASA and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oncoinvent ASA's current EV-to-FCF is -0.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncoinvent ASA stock overvalued right now?
Oncoinvent ASA (CHIX:ONCINO) has a current EV-to-FCF of -0.50. The stock's GF Value™ is kr19,149.99, compared to a current price of kr1,039.91 — trading 94.6% below its estimated fair value. The current EV-to-FCF is -0.50. Oncoinvent ASA's overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Oncoinvent ASA (CHIX:ONCINO), the current EV-to-FCF is -0.50 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncoinvent ASA (CHIX:ONCINO) Overvalued in 2026?
Based on GuruFocus' analysis, Oncoinvent ASA stock appears to be undervalued.
The current stock price of kr1,039.91 is trading 94.6% below its estimated GF Value™ of kr19,149.99.
Key valuation signals for CHIX:ONCINO:
EV-to-FCF: -0.50
GF Value™: kr19,149.99 vs. price of kr1,039.91 (94.6% below fair value)
No single metric tells the full story. See the CHIX:ONCINO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncoinvent ASA is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. Its key product candidate is Radspherin, a receptor-independent alpha radiation therapy that leverages the anatomy of the abdominal cavity to destroy residual micrometastases using a single, localized dose of alpha radiation. Radspherin is currently in clinical development in two indications: peritoneal metastasis from ovarian and colorectal cancer, but it is also relevant for treating peritoneal metastasis from other cancer types and potentially metastatic cancer in other body cavities. Geographically, the company operates in Norway.
36GF Score
Get the complete analysis for CHIX:ONCINO
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:ONCINO has been successfully added to your 
